fanttest
https://www.fanttest.com/products/human-papilloma-virus-hpv-antigen-rapid-test/
Screening for HPV 16, 18 subtypes of high-risk. Early screening for cancer. This product is designed for the in vitro characterization of positive human papillomavirus L1 envelope proteins, including HPV-16, -18, in female cervical secretion samples. Human papillomavirus (HPV) infection is the main causative factor of cervical cancer in women. Cervical cancer is a common malignant tumor in women, with a peak incidence age of 30-50 years. About 110 types of HPV have been identified, which are classified into high-risk and low-risk types according to their incidence and carcinogenicity to malignant tumors. Among them, there are 13 high-risk types (including HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 and 68). The results of this kit can be used as an aid in the clinical diagnosis of HPV-16, -18 infections.
Human Papilloma Virus Test Product Background
Infection with human papillomavirus diagnosis (HPV) is a leading cause of cancer among women worldwide with approximately 500,000 new cervical cancer cases and 250,000 deaths each year. Cervical cancer is caused by persistent infection with a group of carcinogenic HPV genotypes (HPV16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and probably HPV68)
The importance of cervical cancer is accentuated by the relatively young average age at incidence and death.
Cervical cancer screening strategies have evolved from cytology-based to HPV-based. Following the identification of HPV as the cause of cervical cancer and the development of sensitive HPV tests, HPV-based screening permits the extension of screening intervals and increased impact per number of lifetime screens.